Posts

Showing posts with the label Dyslipidemia competitive landscape

Dyslipidemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Dyslipidemia is the imbalance of lipids such as cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL). According to the Frederickson phenotype, dyslipidemia is classified into five categories. Phenotype I is a chylomicron abnormality that results in triglycerides higher than the 99 percentiles. Phenotype IIa is characterised primarily by LDL cholesterol abnormalities, with total cholesterol concentrations greater than the 90th percentile and possible apolipoprotein B more significant than the 90 percentile. The phenotype IIb consists of abnormality in LDL and very low-density lipoprotein (VLDL) cholesterol. The most critical complication of dyslipidemia is cardiovascular disease. This can lead to sudden cardiac death, acute myocardial infarction, or stroke. Multiple studies have shown that statins and appropriate dyslipidemia treatment reduce the risk of all-cause mortality, cardiovascular events, and cardiovascular mortality s...